Literature DB >> 9219060

Enzyme immunoassays for specific IgG and IgE antibodies to Pichia pastoris components in normal humans.

W Ohtani1, K Kobayashi, T Ohmura.   

Abstract

We developed enzyme immunoassays for human anti-Pichia pastoris components (PPC) IgG and anti-PPC IgE antibody titers. Anti-PPC IgG antibody assay were performed using antigen-coated plate and anti-human IgG peroxidase conjugate. The intra- and interassay coefficients of variation (CV) of anti-PPC IgG antibody were 1.83-2.51% and 1.97-2.76%, respectively. The anti-PPC IgE antibody assay was performed using an anti-IgE monoclonal antibody-coated plate, biotin-labeled PPC and avidin-labeled peroxidase, which was not subject to interference by the high titer of anti-PPC IgG antibody. The intra- and interassay CV were 3.83-5.34% and 3.56-5.84%, respectively. We determined and compared anti-PPC IgG antibody titers in the 40 normal individuals. We confirmed that a high titer of anti-PPC IgG antibody is contained in all normal human sera and that these antibodies are directed primarily to mannan by immunoblotting analysis. The ratio of the maximum to minimum anti-PPC IgG antibody titers in normal individuals was > 8,000. Anti-PPC IgG antibody titers did not correlate with the age. However, we did not detect anti-PPC IgE antibody in normal individuals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219060      PMCID: PMC6760742     

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  28 in total

1.  Lack of induction of IgE and IgG antibodies to yeast in humans immunized with recombinant hepatitis B vaccines.

Authors:  G Wiedermann; O Scheiner; F Ambrosch; D Kraft; H Kollaritsch; P Kremsner; P Hauser; E Simoen; F E André; A Safary
Journal:  Int Arch Allergy Appl Immunol       Date:  1988

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  IgE-binding components of baker's yeast (Saccharomyces cerevisiae) recognized by immunoblotting analysis. Simultaneous IgE binding to mannan and 46-48 kD allergens of Saccharomyces cerevisiae and Candida albicans.

Authors:  O Kortekangas-Savolainen; K Kalimo; K Lammintausta; J Savolainen
Journal:  Clin Exp Allergy       Date:  1993-03       Impact factor: 5.018

4.  The radioallergosorbent test in 1981--limitations and refinements.

Authors:  N F Adkinson
Journal:  J Allergy Clin Immunol       Date:  1981-02       Impact factor: 10.793

5.  IgE and eosinophil regulation in a murine model of allergic aspergillosis.

Authors:  V P Kurup; H Choi; P S Murali; R L Coffman
Journal:  J Leukoc Biol       Date:  1994-11       Impact factor: 4.962

6.  Factors influencing the immunogenicity of the haptenic drug chlorhexidine in mice. II. The role of the carrier and adjuvants in the induction of IgE and IgG anti-hapten responses.

Authors:  G T Layton; D R Stanworth; H E Amos
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

7.  The positive and negative cis-acting elements for methanol regulation in the Pichia pastoris AOX2 gene.

Authors:  H Ohi; M Miura; R Hiramatsu; T Ohmura
Journal:  Mol Gen Genet       Date:  1994-06-03

8.  Clinical evaluation of biosynthetic glucagon treatment for recovery from hypoglycemia developed in diabetic patients. The GL-G Hypoglycemia Study Group.

Authors:  M Namba; T Hanafusa; N Kono; S Tarui
Journal:  Diabetes Res Clin Pract       Date:  1993-02       Impact factor: 5.602

9.  Acetolysis of Pichia pastoris IFO 0948 strain mannan containing alpha-1,2 and beta-1,2 linkages using acetolysis medium of low sulfuric acid concentration.

Authors:  H Kobayashi; N Shibata; S Suzuki
Journal:  Arch Biochem Biophys       Date:  1986-03       Impact factor: 4.013

10.  Skin prick test reactions to brewer's yeast (Saccharomyces cerevisiae) in adult atopic dermatitis patients.

Authors:  O Kortekangas-Savolainen; K Lammintausta; K Kalimo
Journal:  Allergy       Date:  1993-04       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.